Global Initiatives

Natural disasters, such as Hurricane Maria, may have contributed to more acute shortages than previously experienced. By Jorge Garcia, PharmD, MS, MHA, MBA, and Dina B. Dumercy, PharmD, BCOP, BCPS Posted: June 2018 Drug shortages in oncology date back to the late 1980s, when there was a scarcity of paclitaxel. Since then, with an increase…

By Masahiro Yanagawa, MD, PhD, andNoriyuki Tomiyama, MD, PhD Posted: April 2018 Improvement in computer capacity, the expansion of computer networks, and the emergence of big data have resulted in a boom in artificial intelligence (AI). AI is structured by building a model that can imitate the human brain. Deep Learning (DL) is one of…

By Pedro N. Aguiar Jr., MD, MSc, andGilberto L. Lopes Jr., MD, MBA Posted: April 2018 After often-painful but effective and still incomplete economic reforms, more rational government spending, and the increased trade brought about by globalization, Latin America has lifted itself out of the misery of its recent past and has started to tackle…

By AnnMarie Estrada, IASLC Foundation Director Posted: February 2018 When you think of the IASLC, you think about professional development, networking, and renowned international lung cancer conferences. When you consider the IASLC Foundation, what comes to mind? At first, you may think of fellowships and grants. When we look a little closer, we begin to…

By Cynthia L. Kryder, MSPosted: December 2017 Despite genomic advances in the treatment of advanced lung cancer over the past decade, few breakthroughs have emerged in the adjuvant treatment of patients with resected non-small cell lung cancer (NSCLC) in whom there is a 50% chance that the cancer will recur after standard treatment. Consequently, the…

By Fabrice Barlesi, MD, PhD, and Eric Vallières, MD, FRCSC An article by Cynthia Kryder and Ramón Rami-Porta in the IASLC Lung Cancer News recently highlighted the innovations of the 8th Edition of the TNM Classification of Lung Cancer. This new classification is more detailed than the 7th edition, as it now contains 11 T…

By Gian Piero Bandelli, MD, Federica Ferraresi, WALCE Advocate, and Silvia Novello, MD, PhD On the occasion of World No Tobacco Day 2017, Women Against Lung Cancer in Europe (WALCE), in partnership with European Network for Smoking and Tobacco Prevention (ENSP), European Lung Foundation (ELF), European Respiratory Society (ERS), Fondazione Insieme Contro il Cancro, and…

By Cynthia L. Kryder, MS, CCC-Sp Rearrangements in the anaplastic lymphoma kinase (ALK) gene occur in approximately 2% to 7% of patients with advanced non-small cell lung cancer (NSCLC).1 For patients with advanced ALK-positive NSCLC, the current firstline standard of care is crizotinib, a MET tyrosine kinase inhibitor (TKI) with activity in ALK-rearranged NSCLC. It…

Posted: June 2017 By Νiki Karachaliou, MD, PhD The identification of oncogenic driver alterations in non-small cell lung cancer (NSCLC), such as EGFR mutations and ALK rearrangements, each of which confers sensitivity to small tyrosine kinase inhibitors, has made EGFR and ALK testing a necessity in routine molecular pathologic diagnosis. Furthermore, next-generation sequencing (NGS) studies…

Posted: April 2017 By Keightley Amen, BA, ELS To help ensure that high-quality thoracic oncology care is available throughout the world and well into the future, the IASLC offers an International Mentorship Program to support early-career physicians and researchers from economically developing countries. The competitive program provides each winner with a full scholarship to the…